The JM Smucker Company

Equities

SJM

US8326964058

Market Closed - Nyse Other stock markets 01:30:02 09/05/2026 am IST			5-day change	1st Jan Change
99.25 ^USD	-0.19%		+2.35%	+1.47%

04/05	Bernstein Adjusts Price Target on J.M. Smucker to $134 From $145, Maintains Outperform Rating	MT
04/05	Jefferies Adjusts Price Target on J.M. Smucker to $128 From $133, Maintains Buy Rating	MT

Transcript : The J. M. Smucker Company, Q1 2025 Earnings Call, Aug 28, 2024

Published on 08/28/2024 at 06:30 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to The J. M. Smucker Company's Fiscal 2025 First Quarter Earnings Question-and-Answer session. This conference call is being

[

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about The JM Smucker Company

04/05	Bernstein Adjusts Price Target on J.M. Smucker to $134 From $145, Maintains Outperform Rating	MT
04/05	Jefferies Adjusts Price Target on J.M. Smucker to $128 From $133, Maintains Buy Rating	MT
04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
24/04	BNP Paribas Adjusts J.M. Smucker Price Target to $120 From $125, Maintains Outperform Rating	MT
24/04	BNP Paribas Adjusts J.M. Smucker Price Target to $120 From $125, Maintains Outperform Rating	MT
23/04	Morgan Stanley Adjusts Price Target on J.M. Smucker to $104 From $118, Maintains Equalweight Rating	MT
21/04	Stifel Adjusts Price Target on J.M. Smucker to $100 From $120, Maintains Hold Rating	MT
17/04	J.M. Smucker Keeps Quarterly Dividend at $1.10 a Share, Payable June 1 to Holders of Record May 15	MT
17/04	The J.M. Smucker Co. Approves Regular Dividend on the Common Shares, Payable on June 1, 2026	CI
14/04	Barclays Adjusts Price Target on J.M. Smucker to $103 From $125, Maintains Equalweight Rating	MT
14/04	BTIG Initiates J.M. Smucker at Buy With $120 Price Target	MT
14/04	US Equity Markets Rise Amid Expectations for US-Iran Peace Deal	MT
13/04	Top Midday Stories: Goldman Shares Fall Despite Q1 Earnings Topping Estimates; Revolution's Pancreatic Cancer Drug Met Key Study Goals	MT
13/04	Conagra Brands, Inc. Announces Chief Executive Officer Changes	CI
13/04	Conagra Brands, Inc. Announces Management Changes	CI